Author + information
- Jay N. Cohn, MD* ()
- ↵*Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455
Dr. Ghali may be expecting too much from post hoc subgroup analysis of clinical trial data (1). The sample size in the low blood pressure subgroup (n = 132) is too small to offer any power to detect a difference in hazard ratio from the other subgroups. Furthermore, far fewer patients in the low blood pressure subgroup were at target dose of carvedilol and far more were permanently discontinued because of adverse effects. Indeed, the similar benefit of carvedilol in this subgroup despite the lower compliance with the drug regimen supports the suggestion that the drug, if tolerated, has a striking benefit in this population.
- American College of Cardiology Foundation